Feb 17, 2026 05:31PM
Feb 6, 2026 06:45AM
Feb 6, 2026 06:45AM
Nov 24, 2025 07:02AM
Nov 24, 2025 07:00AM
Oct 1, 2025 01:20PM
Sep 17, 2025 04:31PM Arvinas and Pfizer to out-license vepdegestrant commercialization rights
Sep 17, 2025 04:30PM
Aug 8, 2025 04:05PM
Aug 8, 2025 04:05PM
Jun 13, 2025 11:43AM
Dec 11, 2024 09:44AM
Aug 6, 2024 08:30AM
Jul 30, 2024 06:45AM Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
Jun 13, 2024 10:57AM
Apr 29, 2024 06:47AM
Apr 29, 2024 06:45AM
Feb 14, 2024 08:30AM
Jan 30, 2024 06:45AM
Jan 9, 2024 06:45AM
Jan 9, 2024 06:45AM TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
Jan 9, 2024 06:45AM
Dec 11, 2023 04:30PM
Dec 11, 2023 04:30PM
Nov 7, 2023 01:00AM
Aug 23, 2023 08:15PM
Aug 23, 2023 06:46AM
Aug 23, 2023 06:45AM FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
Aug 1, 2023 06:45AM
Jun 27, 2023 06:45AM
Jun 27, 2023 06:45AM
Jun 1, 2023 05:47AM
May 31, 2023 05:49PM
May 18, 2023 04:59PM
May 18, 2023 04:59PM FDA Advisory Committee Votes in Support of Approval for Pfizer’s Vaccine Candidate to Help Prevent RSV in Infants Through Maternal Immunization
May 2, 2023 06:45AM
Apr 4, 2023 06:46AM
Apr 4, 2023 06:45AM
Mar 16, 2023 03:18PM
Mar 16, 2023 03:18PM
Feb 28, 2023 04:40PM
Feb 28, 2023 04:40PM Pfizer Receives Positive FDA Advisory Committee Votes Supporting Potential Approval for Vaccine Candidate to Help Combat RSV in Older Adults
Feb 21, 2023 06:45AM
Feb 21, 2023 06:45AM
Feb 16, 2023 06:45AM
Feb 16, 2023 06:45AM
Jan 31, 2023 06:45AM
Jan 6, 2023 06:47AM
Jan 6, 2023 06:45AM U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Pfizer’s 20-Valent Pneumococcal Conjugate Vaccine in Infants and Children
Jan 4, 2023 08:39AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All